Immunome (IMNM) Short-term Investments (2023 - 2026)

Immunome (IMNM) has 3 years of Short-term Investments data on file, last reported at $124.2 million in Q2 2025.

• Quarterly Short-term Investments rose 9.91% year-over-year to $124.2 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $124.2 million (up 9.91% YoY) and the FY2024 annual result came in at $74.0 million, up 87.4% from the prior year.
• Short-term Investments rose to $124.2 million in Q2 2025, from $59.7 million in the prior quarter.
• In the past five years, Short-term Investments ranged from a high of $124.2 million in Q2 2025 to a low of $39.5 million in Q4 2023.
• A 3-year average of $76.4 million and a median of $74.0 million in 2024 frame the typical range for Short-term Investments.
• Annual changes were most pronounced in 2024 — Short-term Investments soared 87.4% — and 2025, when it climbed 9.91%.
• Tracing IMNM's Short-term Investments over 3 years: stood at $39.5 million in 2023, then surged by 87.4% to $74.0 million in 2024, then soared by 67.95% to $124.2 million in 2025.
• The last three Short-term Investments figures came in at $124.2 million (Q2 2025), $59.7 million (Q1 2025), and $74.0 million (Q4 2024), per Business Quant data.